title: The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease.
abstract: The pathophysiology underlying several metabolic diseases, such as obesity, type 2 diabetes mellitus, and atherosclerosis, involves a state of chronic low-level inflammation. Evidence is now emerging that the nuclear receptor Peroxisome Proliferator-Activated Receptor (PPAR)beta/delta ameliorates these pathologies partly through its anti-inflammatory effects. PPARbeta/delta activation prevents the production of inflammatory cytokines by adipocytes, and it is involved in the acquisition of the anti-inflammatory phenotype of macrophages infiltrated in adipose tissue. Furthermore, PPARbeta/delta ligands prevent fatty acid-induced inflammation in skeletal muscle cells, avoid the development of cardiac hypertrophy, and suppress macrophage-derived inflammation in atherosclerosis. These data are promising and suggest that PPARbeta/delta ligands may become a therapeutic option for preventing the inflammatory basis of metabolic diseases.
authors: Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain.
authors: Teresa
authors: T
authors: Coll
authors: Emma
authors: E
authors: Barroso
authors: David
authors: D
authors: Alvarez-Guardia
authors: Lucía
authors: L
authors: Serrano
authors: Laia
authors: L
authors: Salvadó
authors: Manuel
authors: M
authors: Merlos
authors: Xavier
authors: X
authors: Palomer
authors: Manuel
authors: M
authors: Vázquez-Carrera